JUR-003 in Adult Patients With Metastatic Prostate Cancer

Part of paid clinical trials in Grand Rapids, Michigan.

Sponsor
Juri Biosciences, Inc.
Study ID
NCT07824349
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Metastatic Castration Resistant Prostate Cancer
  • Metastatic Hormone Sensitive Prostate Cancer
  • Oligometastatic Prostate Cancer (OMPC)

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JUR-003 — BIOLOGICAL
    JUR-003 will be administered intravenously.

Study Details

JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of JUR-003 in patients with prostate cancer. This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.

Key Dates

First listed
Sep 17, 2026
Start date
Sep 30, 2026
Status verified
Jul 2026
Primary completion
Jun 30, 2030
Completion
Jun 30, 2030

Study Design

Enrollment
210 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1 (Dose Escalation)
    Participants will receive JUR-003 to determine the recommended dose for expansion (RDE) regimen.
  • Experimental: Part 2 (Dose Expansion)
    Participants will receive JUR-003 at the RDE as determined in Part 1 of the study to confirm the safety and anti-tumor activity.

Primary Outcome Measure

Safety and Tolerability [ Time Frame: 2 years ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
START MidwestGrand RapidsMichigan49546-
START New YorkLake SuccessNew York11042-
SCRI Oncology PartnersNashvilleTennessee37203-

Find similar trials in Grand Rapids, MI

By research site
START Midwest· Grand Rapids, MISTART New York· Lake Success, NYSCRI Oncology Partners· Nashville, TN

Related Studies